Testing robotic surgery for HPV-related throat cancer patients
Part of Cancer clinical trials.
This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you have a type of throat cancer linked to HPV that is p16-positive on lab testing
- Your scanable primary tumor can be fully removed by surgery (no distant spread)
- Before surgery, your HPV blood test (NavDX) must be detectable at the required level (at least 10 fragments/mL)
- After surgery, your repeat HPV blood test (1–5 weeks later) must be undetectable (less than 5 fragments/mL)
- You haven’t had prior cancer treatment to the head and neck (except limited biopsy/tonsil removal), and you’re not an active smoker
- Your health tests (kidney function, blood counts) must be adequate, and you must be able to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if monitoring cancer DNA left in your blood after surgery can help decide if you need additional treatment. It is for people with HPV-positive oropharynx (throat) cancer who have a certain amount of cancer DNA detected before surgery.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This Phase 2 trial studies whether 5-azacytidine and nivolumab (alone and/or together) can work well and be tolerated in people with HPV-related throat cancer that can be surgically removed. The goal is to help shrink or control the cancer before resection and learn more from added tumor samples.
This trial is testing a surgical approach for people with HPV-related oropharyngeal cancer that is stage I or II (but not the very smallest). The goal is to see if removing the tumor through the mouth and taking out neck lymph nodes is effective and safe. It may be an option if you are healthy enough for surgery.
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.